BioElectronics Corporation has recently published results for two significant trials involving their Pulsed Shortwave Therapy (PSWT) devices, ActiPatch (for humans) and RecoveryRx (for veterinary use).
Here is a summary of the findings for each:
1. Stanford University Thumb Study
This study focused on Thumb Carpometacarpal (CMC) Osteoarthritis, one of the most common and debilitating forms of hand arthritis.
Study Design: A double-blind, randomized, controlled trial involving 61 adults. Participants used either an active ActiPatch device or a sham (placebo) device for approximately 8 hours per night over 4 weeks.
Key Findings:
Sustained Relief: While both the active and sham groups saw initial pain reduction at the 4-week mark (likely due to a placebo effect or the physical "splinting" feel of the patch), only the ActiPatch group maintained significant pain relief at the 6-week mark (two weeks after stopping use).
Statistical Significance: The difference in pain reduction at week 6 was highly significant (p = 0.02).
Functionality: Improvements were also noted in hand function (measured via PRWHE scores) and "Single Assessment Numeric Evaluation" (SANE) scores.
Conclusion: The device provides a non-invasive, drug-free way to manage thumb arthritis pain with lasting effects even after treatment sessions end.
2. Veterinary Study (RecoveryRx)
This clinical trial investigated the efficacy of RecoveryRx for managing symptoms in canines with osteoarthritis.
Study Design: A randomized, double-blind, placebo-controlled trial involving 49 dogs over a 14-day period.
Key Findings:
Pain & Discomfort: The treatment group saw a 44% reduction in subjective discomfort scores, whereas the placebo group showed no improvement (p = 0.0001).
Mobility: There was a significant increase in Passive Range of Motion (PROM) in the affected limbs of the treated dogs compared to the control group (p < 0.01).
Overall Quality of Life: 96% of the dogs in the treatment group showed improved behavioral changes, increased mobility, or both. Most of these improvements were observed within the first 8 days of use.
Conclusion: The study suggests that RecoveryRx is a potent tool for veterinary pain management, offering a way to improve quality of life and mobility in aging or arthritic pets without the side effects of long-term NSAID use.
Here is a summary of the findings for each:
1. Stanford University Thumb Study
This study focused on Thumb Carpometacarpal (CMC) Osteoarthritis, one of the most common and debilitating forms of hand arthritis.
Study Design: A double-blind, randomized, controlled trial involving 61 adults. Participants used either an active ActiPatch device or a sham (placebo) device for approximately 8 hours per night over 4 weeks.
Key Findings:
Sustained Relief: While both the active and sham groups saw initial pain reduction at the 4-week mark (likely due to a placebo effect or the physical "splinting" feel of the patch), only the ActiPatch group maintained significant pain relief at the 6-week mark (two weeks after stopping use).
Statistical Significance: The difference in pain reduction at week 6 was highly significant (p = 0.02).
Functionality: Improvements were also noted in hand function (measured via PRWHE scores) and "Single Assessment Numeric Evaluation" (SANE) scores.
Conclusion: The device provides a non-invasive, drug-free way to manage thumb arthritis pain with lasting effects even after treatment sessions end.
2. Veterinary Study (RecoveryRx)
This clinical trial investigated the efficacy of RecoveryRx for managing symptoms in canines with osteoarthritis.
Study Design: A randomized, double-blind, placebo-controlled trial involving 49 dogs over a 14-day period.
Key Findings:
Pain & Discomfort: The treatment group saw a 44% reduction in subjective discomfort scores, whereas the placebo group showed no improvement (p = 0.0001).
Mobility: There was a significant increase in Passive Range of Motion (PROM) in the affected limbs of the treated dogs compared to the control group (p < 0.01).
Overall Quality of Life: 96% of the dogs in the treatment group showed improved behavioral changes, increased mobility, or both. Most of these improvements were observed within the first 8 days of use.
Conclusion: The study suggests that RecoveryRx is a potent tool for veterinary pain management, offering a way to improve quality of life and mobility in aging or arthritic pets without the side effects of long-term NSAID use.
2
